Toronto, Ontario–(Newsfile Corp. – March 31, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) (“Neural“
or the “Company“), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the Frankfurt Stock Exchange under ticker symbol “M6B”.
Neural CEO Ian Campbell commented, “Listing our shares on a Frankfurt Stock Exchange will provide us with access to an expanded international investor audience, which we expect to lead to greater liquidity and an internationally diversified shareholder base as we continue to expand our operations. Furthermore, considering our proposed acquisition of Hanf.com, as outlined in our press release dated Oct 3, 2024, we expect that a Frankfurt listing will also serve as a marketing tool to expand awareness of the Hanf.com brand with consumers and investors alike. We believe that the combination of developing new high-impact therapies, while capturing the benefits of strong fundamentals through growing retail sales in Germany once we have completed the Hanf.com transaction, will generate market traction as we continue to pro-actively engage with new and existing audiences.“
The Frankfurt Stock Exchange, operated by Deutsche Börse AG, is one of the world’s largest securities trading platforms and a key financial hub for European and international investors. With approximately C$2 trillion in trading transactions in 2024[1], Frankfurt is one of the largest and most liquid exchanges globally. Frankfurt’s prominence enables companies to engage with both institutional and retail investors from across the globe, while the ‘home market’ effect provides a strong connection to companies with operations in Germany, a market with over 80 million people[2].
About Neural Therapeutics
Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company’s innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy.
For further inquiries, please contact:
Neural Therapeutics Inc.
Ian Campbell, CEO
E: icampbell@neuraltherapeutics.ca
T: +1 (647) 697-NURL (6875)
Marc Lakmaaker
E: mlakmaaker@gmail.com
T: +1.647.289.6640